<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34946825</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Phenoconversion from Spastic Paraplegia to ALS/FTD Associated with <i>CYP7B1</i> Compound Heterozygous Mutations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1876</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes12121876</ELocationID><Abstract><AbstractText>Biallelic mutations in the <i>CYP7B1</i> gene lead to spastic paraplegia-5 (SPG5). We report herein the case of a patient whose clinical symptoms began with progressive lower limb spasticity during childhood, and who secondly developed amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) at the age of 67 years. Hereditary spastic paraplegia (HSP) gene analysis identified the compound heterozygous mutations c.825T&gt;A (pTyr275*) and c.1193C&gt;T (pPro398Leu) in <i>CYP7B1</i> gene. No other pathogenic variant in frequent ALS/FTD causative genes was found. The <i>CYP7B1</i> gene seems, therefore, to be the third gene associated with the phenoconversion from HSP to ALS, after the recently described <i>UBQLN2</i> and <i>ERLIN2</i> genes. We therefore expand the phenotype associated with <i>CYP7B1</i> biallelic mutations and make an assumption about a link between cholesterol dyshomeostasis and ALS/FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theuriet</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5694-3759</Identifier><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, CEDEX, 69677 Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegat</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, CEDEX, 69677 Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblanc</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut NeuroMyoG&#xe8;ne, CNRS UMR5310, INSERM U1217, Facult&#xe9; de M&#xe9;decine Rockefeller, Universit&#xe9; Claude Bernard Lyon I, 8 Avenue Rockefeller, CEDEX 08, 69373 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vukusic</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Neurologie, Scl&#xe9;rose en Plaques, Pathologies de la My&#xe9;line et Neuro-Inflammation et Fondation Eug&#xe8;ne Devic EDMUS Pour la Scl&#xe9;rose en Plaques, H&#xf4;pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 59 Boulevard Pinel, CEDEX, 69677 Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cazeneuve</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5195-9348</Identifier><AffiliationInfo><Affiliation>Unit&#xe9; Fonctionnelle de Neurog&#xe9;n&#xe9;tique Mol&#xe9;culaire et Cellulaire, D&#xe9;partement de G&#xe9;n&#xe9;tique M&#xe9;dicale, GHU AP-HP, Sorbonne Universit&#xe9;, B&#xe2;timent de la Pharmacie Secteur Salp&#xea;tri&#xe8;re 47/83, Boulevard de l'H&#xf4;pital, CEDEX 13, 75651 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millecamps</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0745-6735</Identifier><AffiliationInfo><Affiliation>Institut du Cerveau, ICM, Inserm U1127, CNRS UMR7225, Sorbonne Universit&#xe9;, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, 47 Boulevard de l'H&#xf4;pital, CEDEX, 75646 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banneau</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit&#xe9; Fonctionnelle de Neurog&#xe9;n&#xe9;tique Mol&#xe9;culaire et Cellulaire, D&#xe9;partement de G&#xe9;n&#xe9;tique M&#xe9;dicale, GHU AP-HP, Sorbonne Universit&#xe9;, B&#xe2;timent de la Pharmacie Secteur Salp&#xea;tri&#xe8;re 47/83, Boulevard de l'H&#xf4;pital, CEDEX 13, 75651 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillaud-Bataille</LastName><ForeName>Marine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit&#xe9; Fonctionnelle de Neurog&#xe9;n&#xe9;tique Mol&#xe9;culaire et Cellulaire, D&#xe9;partement de G&#xe9;n&#xe9;tique M&#xe9;dicale, GHU AP-HP, Sorbonne Universit&#xe9;, B&#xe2;timent de la Pharmacie Secteur Salp&#xea;tri&#xe8;re 47/83, Boulevard de l'H&#xf4;pital, CEDEX 13, 75651 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3952-9265</Identifier><AffiliationInfo><Affiliation>Centre SLA de Lyon, H&#xf4;pital Neurologique P. Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, 59 Boulevard Pinel, CEDEX, 69677 Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut NeuroMyoG&#xe8;ne, CNRS UMR5310, INSERM U1217, Facult&#xe9; de M&#xe9;decine Rockefeller, Universit&#xe9; Claude Bernard Lyon I, 8 Avenue Rockefeller, CEDEX 08, 69373 Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.-</RegistryNumber><NameOfSubstance UI="D013250">Steroid Hydroxylases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.23</RegistryNumber><NameOfSubstance UI="D000072474">Cytochrome P450 Family 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.29</RegistryNumber><NameOfSubstance UI="C499571">CYP7B1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072474" MajorTopicYN="N">Cytochrome P450 Family 7</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010264" MajorTopicYN="N">Paraplegia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013250" MajorTopicYN="N">Steroid Hydroxylases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS/FTD</Keyword><Keyword MajorTopicYN="N">CYP7B1</Keyword><Keyword MajorTopicYN="N">SPG5</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">hereditary spastic paraplegia</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34946825</ArticleId><ArticleId IdType="pmc">PMC8700784</ArticleId><ArticleId IdType="doi">10.3390/genes12121876</ArticleId><ArticleId IdType="pii">genes12121876</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sch&#xfc;le R., Wiethoff S., Martus P., Karle K.N., Otto S., Klebe S., Klimpe S., Gallenm&#xfc;ller C., Kurzwelly D., Henkel D., et al. Hereditary Spastic Paraplegia: Clinicogenetic Lessons from 608 Patients: Hereditary Spastic Paraplegia. Ann. Neurol. 2016;79:646&#x2013;658. doi: 10.1002/ana.24611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24611</ArticleId><ArticleId IdType="pubmed">26856398</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ls L., Rattay T.W., Martus P., Meisner C., Baets J., Fischer I., J&#xe4;gle C., Fraidakis M.J., Martinuzzi A., Saute J.A., et al. Hereditary Spastic Paraplegia Type 5: Natural History, Biomarkers and a Randomized Controlled Trial. Brain. 2017;140:3112&#x2013;3127. doi: 10.1093/brain/awx273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx273</ArticleId><ArticleId IdType="pmc">PMC5841036</ArticleId><ArticleId IdType="pubmed">29126212</ArticleId></ArticleIdList></Reference><Reference><Citation>Marelli C., Lamari F., Rainteau D., Lafourcade A., Banneau G., Humbert L., Monin M.-L., Petit E., Debs R., Castelnovo G., et al. Plasma oxysterols: Biomarkers for diagnosis and treatment in spastic paraplegia type 5. Brain. 2017;141:72&#x2013;84. doi: 10.1093/brain/awx297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx297</ArticleId><ArticleId IdType="pubmed">29228183</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganelli F., Pisciotta C., Dubbioso R., Iodice R., Criscuolo C., Ruggiero L., Michele G.D., Santoro L. Electrophysiological Characterisation in Hereditary Spastic Paraplegia Type 5. Clin. Neurophysiol. 2011;122:819&#x2013;822. doi: 10.1016/j.clinph.2010.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2010.10.025</ArticleId><ArticleId IdType="pubmed">21111673</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic Lateral Sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A., Kenna K.P., Renton A.E., Ticozzi N., Faghri F., Chia R., Dominov J.A., Kenna B.J., Nalls M.A., Keagle P., et al. Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97:1268&#x2013;1283.e6. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Teyssou E., Chartier L., Amador M.-D.-M., Lam R., Lautrette G., Nicol M., Machat S., Da Barroca S., Moigneu C., Mairey M., et al. Novel UBQLN2 Mutations Linked to Amyotrophic Lateral Sclerosis and Atypical Hereditary Spastic Paraplegia Phenotype through Defective HSP70-Mediated Proteolysis. Neurobiol. Aging. 2017;58:239.e11&#x2013;239.e20. doi: 10.1016/j.neurobiolaging.2017.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.06.018</ArticleId><ArticleId IdType="pubmed">28716533</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador M.-D.-M., Muratet F., Teyssou E., Banneau G., Danel-Brunaud V., Allart E., Antoine J.-C., Camdessanch&#xe9; J.-P., Anheim M., Rudolf G., et al. Spastic Paraplegia Due to Recessive or Dominant Mutations in ERLIN2 Can Convert to ALS. Neurol Genet. 2019;5:e374. doi: 10.1212/NXG.0000000000000374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000374</ArticleId><ArticleId IdType="pmc">PMC6927358</ArticleId><ArticleId IdType="pubmed">32042907</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J., Gordon P.H. Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: Discrete entities or spectrum? Amyotroph. Lateral Scler. 2005;6:8&#x2013;16. doi: 10.1080/14660820410021267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410021267</ArticleId><ArticleId IdType="pubmed">16036421</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Al-Chalabi A., Baker M.R., Cui L.-Y., de Carvalho M., Eisen A., Grosskreutz J., Hardiman O., Henderson R., Matamala J.M., et al. A Proposal for New Diagnostic Criteria for ALS. Clin. Neurophysiol. 2020;131:1975&#x2013;1978. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., et al. Sensitivity of Revised Diagnostic Criteria for the Behavioural Variant of Frontotemporal Dementia. Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Goizet C., Boukhris A., Durr A., Beetz C., Truchetto J., Tesson C., Tsaousidou M., Forlani S., Guyant-Marechal L., Fontaine B., et al. CYP7B1 Mutations in Pure and Complex Forms of Hereditary Spastic Paraplegia Type 5. Brain. 2009;132:1589&#x2013;1600. doi: 10.1093/brain/awp073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp073</ArticleId><ArticleId IdType="pubmed">19439420</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber M.D., Vesely P.W., Datta K., Gerace L. Erlins Restrict SREBP Activation in the ER and Regulate Cellular Cholesterol Homeostasis. J. Cell Biol. 2013;203:427&#x2013;436. doi: 10.1083/jcb.201305076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201305076</ArticleId><ArticleId IdType="pmc">PMC3824017</ArticleId><ArticleId IdType="pubmed">24217618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H., Ho W.Y., Chang J., Ling S. Cholesterol Dyshomeostasis in Amyotrophic Lateral Sclerosis: Cause, Consequence, or Epiphenomenon? FEBS J. 2021:16175. doi: 10.1111/febs.16175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16175</ArticleId><ArticleId IdType="pubmed">34469619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.-M., Noh M.-Y., Kim H., Cheon S.-Y., Lee K.M., Lee J., Cha E., Park K.S., Lee K.-W., Sung J.-J., et al. 25-hydroxycholesterol is involved in the pathogenesis of amyotrophic lateral sclerosis. Oncotarget. 2017;8:11855&#x2013;11867. doi: 10.18632/oncotarget.14416.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.14416</ArticleId><ArticleId IdType="pmc">PMC5355309</ArticleId><ArticleId IdType="pubmed">28060747</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>